J Cancer 2021; 12(4):1094-1104. doi:10.7150/jca.51107 This issue
1. Department of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, China
2. Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun 130021, China
3. NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun 130021, China
4. Department of Hematology and Medical Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
High-grade gliomas (HGGs) are the most common primary malignant brain tumors. They have a high degree of malignancy and show invasive growth. The personal treatment plan for HGG is based on the patient's age, performance status, and degree of tumor invasion. The basic treatment plan for HGG involves tumor resection, radiotherapy (RT) with concomitant temozolomide (TMZ), and adjuvant TMZ chemotherapy. The basic radiation technology includes conventional RT, three-dimensional conformal RT, intensity-modulated RT, and stereotactic RT. As our understanding of tumor pathogenesis has deepened, so-called comprehensive treatment schemes have attracted attention. These combine RT with chemotherapy, molecular targeted therapy, immunotherapy, or tumor-treating fields. These emerging treatments are expected to improve the prospects of patients with HGG. In the present article, we review the recent advances in RT and comprehensive treatment for patients with newly diagnosed and recurrent HGG.
Keywords: High-grade glioma, Immunotherapy, Molecular targeted drugs, Radiotherapy, Tumor-treating fields